NEW YORK (GenomeWeb News) – Transgenomic today said that total revenue declined 10 percent in the second quarter and net loss narrowed 62 percent.
 
Receipts for the second quarter ended June 30 slid to $6.2 million from $6.9 million in the same quarter last year.
 
The company spent about $531,000 on R&D in the second quarter, down 9 percent from $581,000 in the comparable period last year.
 
Transgenomic said net loss shrank to $383,000 from $998,000 in Q2 2005.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.